Free Trial

Gilead Sciences Stock Surges on HIV Treatment Trial Success

Vials of liquid on a white table and the logo of Gilead Sciences

Key Points

  • Gilead Sciences (NASDAQ: GILD) surged nearly 10% after announcing 100% efficacy in its Phase 3 HIV prevention trial.
  • The positive trial results come at a critical time as GILD has been down over 15% YTD but has recently broken above key technical resistance levels, signaling a potential shift in momentum.
  • Despite recent struggles, GILD remains attractive with a 4.5% dividend yield, projected earnings growth of 92.8%, and a consensus price target indicating a nearly 22% upside.
  • 5 stocks we like better than Gilead Sciences

Gilead Sciences NASDAQ: GILD saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in its Phase 3 HIV prevention trial, marking the first trial showing zero infections. 

Given the stock's underperformance this year, this news is a significant relief for investors. Let's delve into the trial's details, the stock's recent performance, and its future prospects.

Gilead's Lenacapavir Trial: A Potential Game-Changer

Gilead Sciences Today

Gilead Sciences, Inc. stock logo
GILDGILD 90-day performance
Gilead Sciences
$72.41
-0.15 (-0.21%)
(As of 07/22/2024 ET)
52-Week Range
$62.07
$87.86
Dividend Yield
4.25%
P/E Ratio
201.14
Price Target
$82.88

Gilead's trial found zero cases of HIV infection among 2,134 women who received lenacapavir versus several cases among those on Gilead’s current HIV pills, Truvada and Descovy. Truvada was the first pre-exposure prophylaxis (PrEP) treatment approved by the FDA. However, more testing is needed before lenacapavir can seek FDA approval. Another Phase 3 trial targeting men who have sex with men and other groups is expected to yield results late this year or early next year.

Dr. Linda-Gail Bekker, head of the Desmond Tutu HIV Center, hailed lenacapavir as a potential game-changer for HIV prevention globally.

Breaking Above Resistance: Gilead's Stock Momentum Shift

The positive news comes at a critical time for Gilead. The stock has been in a steep selloff this year, down over 15% YTD and trading well below its 200-day SMA. The recent announcement has, however, helped GILD break above its downtrend resistance and surpass its 50-day and 20-day declining SMAs, signaling a potential shift in momentum.

Going forward, it will be vital to see whether the stock can convert its downtrend resistance into support, as it aims to stage a turnaround and build a base towards its 200-day SMA.

Gilead has significantly lagged its sector, with the iShares Biotechnology ETF NASDAQ: IBB almost flat YTD and consolidating near its 52-week highs. This recent breakthrough could be the catalyst Gilead needs to reverse its downward trend and pair its losses versus the benchmark and its sector.


Balancing Fundamentals and Sentiment: Gilead's Growth Potential

Despite its recent struggles, Gilead presents an attractive proposition for growth investors seeking income. The stock boasts a hefty dividend yield of 4.5% and is projected to grow earnings by 92.8% this year. Analysts are optimistic, with a consensus price target of $83.47, indicating almost 22% upside. Eighteen analysts rate the stock as a Hold. Following the trial news, Robert W. Baird reaffirmed its neutral rating and set a price target of $80, forecasting a nearly 16% upside. The stock is a favorite amongst institutions, boasting 83.6% institutional ownership. Over the previous twelve months, total institutional inflows have been $37.7 billion versus just $4.1 billion in outflows. 

Navigating a Pivotal Moment: Gilead Sciences' Future Prospects

Gilead Sciences MarketRank™ Stock Analysis
Overall MarketRank™
4.92 out of 5
Analyst Rating
Hold
Upside/Downside
14.5% Upside
Short Interest
Healthy
Dividend Strength
Strong
Sustainability
-2.24
News Sentiment
0.77mentions of Gilead Sciences in the last 14 days
Insider Trading
Selling Shares
Projected Earnings Growth
94.61%
See Full Details

Gilead Sciences' recent trial success in HIV prevention is a promising development that could mark a turning point for the stock. While the stock has underperformed the broader sector this year, the breakthrough in the HIV treatment trial and subsequent price surge suggest the potential for recovery. With strong fundamentals, a solid dividend yield, and optimistic analyst projections, Gilead Sciences is a stock to watch closely as it navigates this pivotal moment. Investors should monitor whether GILD can sustain this momentum and convert resistance into support, paving the way for a sustained upward trend.

→ This AI made her leave her job (From Prosper Trading Academy) (Ad)

Should you invest $1,000 in Gilead Sciences right now?

Before you consider Gilead Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.

While Gilead Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report
Ryan Hasson
About The Author

Ryan Hasson

Contributing Author

Technical Analysis, Momentum Trading, Risk Management

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Gilead Sciences (GILD)
4.92 of 5 stars
4.92 / 5 stars
$72.41-0.2%4.25%201.14Hold$82.88
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

How to Trade After Hours Like a Pro
Opportunities Arise as Stock Market Rotates from Big Tech
3 Top Market Leaders Splitting Their Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines